Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Ohana Biosciences
Headquarters: Cambridge, MA, United States of America
Website: https://www.ohanabio.com
Year Founded: 2016
Status: Archived
BioCentury | Sep 25, 2023
Management Tracks
Remy Sukhija leaving Madrigal as CCO
Plus: Editas hires Caren Deardorf as chief commercial and strategy officer, and updates from ProFound and hC
BioCentury | Jul 13, 2022
Emerging Company Profile
Epic Bio: Epigenome editing via compact components
Horizons Ventures leads $55M series A for start-up developing compact epigenome editors with all-in-one AAV delivery
BioCentury | Feb 11, 2022
Management Tracks
Silberstein joins GentiBio as CFO
Plus new CTO, CDO at Finch; and updates from Generation Bio, Atea and more
BioCentury | Jul 8, 2021
Management Tracks
Chin returns to Arix to rebuild investment team as three more depart; plus ADCendo, Magenta, Junshi, Valneva, Q32 Bio, Outlook, Quotient Catalyst, Kaleido, Amolyt and more
Mark Chin is rejoining Arix Bioscience plc (LSE:ARIX) as managing director with a mandate to rebuild the VC’s investment team. Managing Director Christian Schetter, Principal John Cassidy
BioCentury | May 1, 2021
Regulation
April 30 Quick Takes: Bilenker has $212M to build newco Treeline’s toolbox; plus Farxiga, Opdivo, BioCryst, Leo, Hikma and more
An SEC filing released Friday revealed that Josh Bilenker and Jeffrey Engelman have $212 million to begin building newly launched Treeline Biosciences Inc.’s toolbox for chasing validated but
BioCentury | Oct 24, 2020
Translation in Brief
UNC Chapel Hill Angelman gene therapy rescues motor function; plus data backing planned Pacylex, Kronos clinical trials and more
BioCentury’s roundup of translational news
BioCentury | Apr 18, 2020
Management Tracks
PTC names Matthew Klein as chief development officer; plus Cardurion, Sangamo, TCR2, Five Prime and more
BioCentury | Apr 2, 2020
Finance
Billion-dollar funds from Arch, Flagship show VCs are open for business
War chests show interest in biotech hasn’t waned amid pandemic
BioCentury | Feb 15, 2020
Management Tracks
Immunomedics names Itri CMO; plus Hua, GenMark, AAM, Vividion, Sophia Genetics, Enterprise, Encoded, Palleon and more
BioCentury | Jan 27, 2020
Emerging Company Profile
Ohana: Looking to the other half of reproductive biology
Ohana is applying single cell sequencing to the unexplored male half of reproductive biology
Items per page:
1 - 10 of 11